“…Of the 24 articles on this Mab, 62.5% originated from European countries. 34,39,41,49,58,59,63,68,69,71,72,79,80,84 The same trend is true for Rituximab (64.3% articles from Europe). 26,27,30,33,35,37,42–44,46–48,54,55,61,62,65,67,73,89 In contrast, Teprotumab has only been tested in the USA.…”